Skip to content

13F-HR filed by GREAT POINT PARTNERS LLC

GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 34 holding rows worth $586,726,411.

Accession
0001172661-24-001436
Filed
2024-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2023

A holdings report, 34 entries on the cover page, a total value of $586,726,411 stated on the cover page (in dollars after the unit check, H1), rows summing to $586,726,411 with VALUE read as dollars as filed, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ALPINE IMMUNE SCIENCES INC02083G100COM3,703,433$70,587,433dollars as filed
CYTOKINETICS INC23282W605COM NEW500,000$41,745,000dollars as filed
UROGEN PHARMA LTDM96088105COMMON STOCK2,620,545$39,308,175dollars as filed
PLIANT THERAPEUTICS INC729139105COM1,823,184$33,017,862dollars as filed
ULTRAGENYX PHARMACEUTICAL IN90400D108COM648,000$30,987,360dollars as filed
XENON PHARMACEUTICALS INC COM98420N105Stock600,000$27,636,000dollars as filed
RAPT THERAPEUTICS INC75382E109COM1,099,753$27,328,862dollars as filed
ALKERMES PLCG01767105SHS875,044$24,273,721dollars as filed
AEROVATE THERAPEUTICS INC008064107COM1,037,690$23,482,925dollars as filed
VAXCYTE INC COM92243G108Stock360,000$22,608,000dollars as filed
EVOLUS INC30052C107COM2,000,000$21,060,000dollars as filed
ANAPTYSBIO INC032724106COM976,981$20,926,933dollars as filed
IMMUNOCORE HLDGS PLC ADS45258D105ADR293,000$20,017,760dollars as filed
NEUROGENE INC64135M105COMMON STOCK994,229$19,268,158dollars as filed
AMICUS THERAPEUTICS INC03152W109COM1,280,500$18,170,295dollars as filed
Tourmaline Bio Inc89157D105Common Stock672,885$17,616,129dollars as filed
ABIVAX SA-00370M103SPONSORED ADS1,550,000$16,585,000dollars as filed
ZURA BIO LTDG9TY5A101COMMON STOCK3,295,000$15,387,650dollars as filed
OPTINOSE INC68404V100COM8,839,939$11,403,521dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock400,000$11,176,000dollars as filed
ARVINAS INC04335A105COM234,082$9,634,815dollars as filed
KARUNA THERAPEUTICS INC48576A100COM30,250$9,574,428dollars as filed
VISTAGEN THERAPEUTICS INC92840H400COM1,858,735$9,553,898dollars as filed
TERNS PHARMACEUTICALS INC COM880881107Stock1,309,975$8,501,738dollars as filed
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK110,607$7,921,673dollars as filed
SAREPTA THERAPEUTICS INC803607100COM80,000$7,714,400dollars as filed
INSMED INC COM PAR $.01457669307Stock225,912$7,001,013dollars as filed
PUMA BIOTECHNOLOGY INC74587V107COMMON STOCK1,093,273$4,733,872dollars as filed
OCULAR THERAPEUTIX INC67576A100COM700,000$3,122,000dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW125,000$2,690,000dollars as filed
ARCELLX INC COMMON STOCK03940C100Stock48,264$2,678,652dollars as filed
MERUS N VN5749R100COM20,000$550,000dollars as filed
AXSOME THERAPEUTICS INC. COM05464T104Stock4,963$395,005dollars as filed
MURAL ONCOLOGY PUB LTD COG63365103ORD SHS11,509$68,133dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001172661-24-001436this filing2024-02-14acceptance time not in the bulk data set